The global sickle cell anemia testing and screening market is estimated to be USD 0.428 billion in 2024 and is expected to reach USD 1.52 billion by 2035, with a CAGR of 12.18% during the forecast period 2025-2035. The market is expected to increase as a result of the following factors: rising prevalence of sickle cell disease (SCD), government initiatives and newborn screening programs, technological advancements in diagnostic testing, growing emphasis on prenatal and antenatal testing, and expanding awareness and education initiatives.
Countries in Africa and Asia are significantly investing in healthcare infrastructure to enhance diagnostic capabilities, aided by international collaborations that establish comprehensive screening facilities in high-burden regions for sickle cell anemia. In a noteworthy development, BillionToOne, a next-generation molecular diagnostics company, announced in June 2024 that it has successfully raised $130 million in an oversubscribed Series D funding round, led by Premji Invest and supported by new investor Neuberger Berman, alongside existing investors such as Adam Street Partners, Baillie Gifford, Hummingbird Ventures, Civilization Ventures, Libertus Capital, and Fifty Years. The funds raised will be utilized for the expansion and scaling of BillionToOne's prenatal and oncology businesses, enhancing their capacity to address critical diagnostic needs in these fields.
By technology, the hemoglobin electrophoresis segment accounted for the highest revenue-grossing segment in the global sickle cell anemia testing and screening market in 2024 owing to the widespread use of this method as a reliable and accurate technique for detecting abnormal hemoglobin variants, especially in regions with a high prevalence of sickle cell disease. For instance, Streck introduced Protein Plus BCT in April 2024, a blood collection tube designed to maintain blood protein levels while being stored. This tube maintains the integrity of the sample for analysis using immunoassay and mass spectrometry. It gives labs logistical flexibility without sacrificing precision. Additionally, the point-of-care tests segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for rapid, easy-to-use testing solutions in remote and resource-limited settings, which facilitate early diagnosis and treatment initiation.
By age group, the newborn screening (12 months and below) segment accounted for the highest revenue-grossing segment in the global sickle cell anemia testing and screening market in 2024 owing to the implementation of mandatory newborn screening programs in various countries, aimed at early detection and management of sickle cell disease to reduce morbidity and mortality rates. For instance, DelveInsight's 'Sickle Cell Disease Competitive Landscape - 2023' report, released in July 2023, offers thorough worldwide coverage of the sickle cell disease competitive domain's future growth potential, the major pharmaceutical companies working to advance the pipeline space, and the available, marketed, and pipeline sickle cell disease drugs in various stages of clinical development. Additionally, the other age groups (1 to 25 & above 60 years) segment is predicted to grow at the fastest CAGR during the forecast period owing to its growing focus on screening for undiagnosed cases and monitoring disease progression in older children, adolescents, and elderly patients, particularly in regions where sickle cell disease has historically been underdiagnosed.
By end-user, the government labs segment accounted for the highest revenue-grossing segment in the global sickle cell anemia testing and screening market in 2024 owing to the significant investment by governments in public health initiatives and large-scale screening programs, especially in high-burden regions. For instance, Bio-Rad Laboratories introduced the Vericheck ddPCR Empty-whole Capsid Kit in October 2024. This kit analyzes AAV samples for capsid and genome titer as well as the proportion of whole capsids using Droplet Digital PCR technology. This affordable tool maximizes gene therapy development while guaranteeing regulatory compliance by producing precise, repeatable results. Additionally, the private labs segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising preference for private diagnostic centers offering faster turnaround times, advanced testing options, and better accessibility for patients seeking specialized care.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high adoption of advanced diagnostic technologies, and strong presence of key market players, along with supportive government initiatives for newborn screening programs and increasing awareness about genetic disorders like sickle cell anemia. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of sickle cell disease, increasing government investments in healthcare infrastructure, expanding newborn screening initiatives, and growing awareness about early diagnosis and treatment options, especially in countries like India and China. For instance, the Government of India launched the National Sickle Cell Anemia Elimination Mission (NSCAEM) on July 1, 2023, with the goal of eliminating sickle cell disease (SCD) by 2047. The press information bureau attributes the mission's success to a nationwide screening effort that focuses on high-prevalence areas, particularly among tribal populations.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
Countries in Africa and Asia are significantly investing in healthcare infrastructure to enhance diagnostic capabilities, aided by international collaborations that establish comprehensive screening facilities in high-burden regions for sickle cell anemia. In a noteworthy development, BillionToOne, a next-generation molecular diagnostics company, announced in June 2024 that it has successfully raised $130 million in an oversubscribed Series D funding round, led by Premji Invest and supported by new investor Neuberger Berman, alongside existing investors such as Adam Street Partners, Baillie Gifford, Hummingbird Ventures, Civilization Ventures, Libertus Capital, and Fifty Years. The funds raised will be utilized for the expansion and scaling of BillionToOne's prenatal and oncology businesses, enhancing their capacity to address critical diagnostic needs in these fields.
By technology, the hemoglobin electrophoresis segment accounted for the highest revenue-grossing segment in the global sickle cell anemia testing and screening market in 2024 owing to the widespread use of this method as a reliable and accurate technique for detecting abnormal hemoglobin variants, especially in regions with a high prevalence of sickle cell disease. For instance, Streck introduced Protein Plus BCT in April 2024, a blood collection tube designed to maintain blood protein levels while being stored. This tube maintains the integrity of the sample for analysis using immunoassay and mass spectrometry. It gives labs logistical flexibility without sacrificing precision. Additionally, the point-of-care tests segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for rapid, easy-to-use testing solutions in remote and resource-limited settings, which facilitate early diagnosis and treatment initiation.
By age group, the newborn screening (12 months and below) segment accounted for the highest revenue-grossing segment in the global sickle cell anemia testing and screening market in 2024 owing to the implementation of mandatory newborn screening programs in various countries, aimed at early detection and management of sickle cell disease to reduce morbidity and mortality rates. For instance, DelveInsight's 'Sickle Cell Disease Competitive Landscape - 2023' report, released in July 2023, offers thorough worldwide coverage of the sickle cell disease competitive domain's future growth potential, the major pharmaceutical companies working to advance the pipeline space, and the available, marketed, and pipeline sickle cell disease drugs in various stages of clinical development. Additionally, the other age groups (1 to 25 & above 60 years) segment is predicted to grow at the fastest CAGR during the forecast period owing to its growing focus on screening for undiagnosed cases and monitoring disease progression in older children, adolescents, and elderly patients, particularly in regions where sickle cell disease has historically been underdiagnosed.
By end-user, the government labs segment accounted for the highest revenue-grossing segment in the global sickle cell anemia testing and screening market in 2024 owing to the significant investment by governments in public health initiatives and large-scale screening programs, especially in high-burden regions. For instance, Bio-Rad Laboratories introduced the Vericheck ddPCR Empty-whole Capsid Kit in October 2024. This kit analyzes AAV samples for capsid and genome titer as well as the proportion of whole capsids using Droplet Digital PCR technology. This affordable tool maximizes gene therapy development while guaranteeing regulatory compliance by producing precise, repeatable results. Additionally, the private labs segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising preference for private diagnostic centers offering faster turnaround times, advanced testing options, and better accessibility for patients seeking specialized care.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high adoption of advanced diagnostic technologies, and strong presence of key market players, along with supportive government initiatives for newborn screening programs and increasing awareness about genetic disorders like sickle cell anemia. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of sickle cell disease, increasing government investments in healthcare infrastructure, expanding newborn screening initiatives, and growing awareness about early diagnosis and treatment options, especially in countries like India and China. For instance, the Government of India launched the National Sickle Cell Anemia Elimination Mission (NSCAEM) on July 1, 2023, with the goal of eliminating sickle cell disease (SCD) by 2047. The press information bureau attributes the mission's success to a nationwide screening effort that focuses on high-prevalence areas, particularly among tribal populations.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
Report Scope:
- Base Year: 2024
- Forecast Period: 2025-2035
- Study Coverage
- Market Forecast by Technology, Age Group, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Sickle Cell Anemia Testing and Screening Market Report 2024 - 2035
Sickle Cell Anemia Testing and Screening Market Analysis & Forecast by Technology 2024 - 2035 (Revenue USD Bn)
- Hemoglobin Electrophoresis
- High-Performance Liquid Chromatography (HPLC)
- Point-of-Care Tests
- Other Tests
Sickle Cell Anemia Testing and Screening Market Analysis & Forecast by Age Group 2024 - 2035 (Revenue USD Bn)
- Newborn Screening (12 months and below)
- Adult Screening (25 to 60 years Other)
- Age Groups (1 to 25 & above 60 years)
Sickle Cell Anemia Testing and Screening Market Analysis & Forecast by End-User 2024 - 2035 (Revenue USD Bn)
- Government Labs
- Private Labs
- Corporate Labs
- PPP (Public-Private-Partnerships)
Sickle Cell Anemia Testing and Screening Market Analysis & Forecast by Region 2024 - 2035 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Sickle Cell Anemia Testing and Screening Market: Technology Estimates & Trend Analysis
8. Sickle Cell Anemia Testing and Screening Market: Age Group Estimates & Trend Analysis
9. Sickle Cell Anemia Testing and Screening Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Sickle Cell Anemia Testing and Screening Market
12. Europe Global Sickle Cell Anemia Testing and Screening Market
13. Asia Pacific Global Sickle Cell Anemia Testing and Screening Market
14. Latin America Global Sickle Cell Anemia Testing and Screening Market
15. MEA Global Sickle Cell Anemia Testing and Screening Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific
- Bio-Rad Laboratories
- Abbott Laboratories
- Siemens Healthineers
- PerkinElmer, Inc.
- Ortho Clinical Diagnostics
- Becton, Dickinson and Company (BD)
- Danaher Corporation
- F. Hoffmann-La Roche Ltd
- Emory Genetics Laboratory
- Grifols
- QIAGEN
- Sonic Healthcare
- LabCorp
- Novacyt
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.43 Billion |
| Forecasted Market Value ( USD | $ 1.52 Billion |
| Compound Annual Growth Rate | 12.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
